ebook_ADHD2019_spanish

REFERENCIAS BIBLIOGRÁFICAS 1. Hinshaw SP, Scheffler RM, Fulton BD, Aase H, Banaschewski T, Cheng W, et al. International variation in treatment procedures for ADHD: social context and recent trends. Psychiatr Serv. 2011;62(5):459-64. 2. Australian Comission on Safety and Quality in Health Care. Attention deficit hyperactivity disorder me- dicines dispensing 17 years and under. In: Australian Comission on Safety and Quality in Health Care. Australian atlas of healthcare variation. Sydney: Australian Commission on Safety and Quality in Health Care, 2015. Cap. 4.10, p. 249-256. 3. Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018;5(2):175-186. 4. Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guide- lines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30. 5. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476-95. 6. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guide- lines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17-37. 7. Hamilton RM, Rosenthal E, Hulpke-Wette M, Graham JG, Sergeant J, European Network of Hyperkine- tic Disorders. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young. 2012;22(1):63-70. 8. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227-46. 9. Coghill D, Seth S. Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. Child Adolesc Psychiatry Ment He- alth. 2015;9:52. 10. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. London: NICE, 2018. 11. Huss M, Chen W, Ludolph AG. Guanfacine extended release: a new pharmacological treatment option in Europe. Clin Drug Investig. 2016;36(1):1-25. 12. Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356-67. 13. Coghill D, Sinita E. Pharmacology for ADHD, tourette syndrome and autism spectrum disorder. In: Huline-Dickens S, editor. Clinical topics in child and adolescent psychiatry. London: Royal College of Psy- chiatrists, 2014. p. 74-93. 14. Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for at- tention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21(9):477-92. 15. Savill NC, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. CNS Drugs. 2015;29(2):131-51. 122 Rohde, Buitelaar, Gerlach & Faraone (editores)